Omega Diagnostics : VISITECT® CD4 commercialisation update

Regulatory Story

Go to market news section

Omega Diagnostics Group PLC - ODX VISITECT® CD4 commercialisation update Released 07:00 18-Jul-2018

RNS Number : 9407U

Omega Diagnostics Group PLC 18 July 2018

Omega Diagnos�cs Group PLC ("Omega" or "the Company")

VISITECT® CD4 commercialisa�on update

Omega (AIM: ODX), the medical diagnos�cs company focused on allergy, food intolerance and infec�ous disease, announces the following update on its VISITECT® CD4 commercialisa�on programme.

The Company announces the appointment of three new dedicated distributors in Ghana, Zambia and Zimbabwe. This follows on from the appointment of their first dedicated distributor for CD4 in Nigeria. All three countries require product registra�on, which has also commenced. Once completed, this will allow business to business sales to commence through the Company's distributors. The three countries have a high prevalence of people living with HIV and have been prior�sed on that basis.

Colin King, CEO of Omega commented: "I am pleased to see our commercialisa�on plan for CD4 taking shape as this is key part of our strategy to delivering shareholder value. This also provides further evidence that our CD4 test (the world's first true point-of-care test) will make a significant difference to people living with HIV in resource-poor environments."

The informa�on communicated in this announcement is inside informa�on for the purposes of Ar�cle 7 of EU Regula�on 596/2014.

Contacts:

Omega Diagnos�cs Group PLC	Tel: [phone]
Colin King, Chief Execu�ve	www.omegadiagnos�cs.com
Kieron Harbinson, Group Finance Director
finnCap Ltd	Tel: [phone]
Geoff Nash/James Thompson (Corporate

Finance)
Camille Gochez/ Abigail Wayne (Corporate
Broking)
Walbrook PR Limited	Tel: [phone] or
[e-mail]
Paul McManus	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please [e-mail] or visitwww.rns.com.

END

UPDEASXXFLFPEFF

CLOSE

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries.Terms and conditions, including restrictions on use and distribution apply.

©2014 London Stock Exchange plc. All rights reserved

VISITECT® CD4 commercialisation update - RNS